Ditchcarbon
  • Contact
  1. Organizations
  2. Ascletis Pha B
Public Profile
Pharmaceutical Preparation Manufacturing
CN
updated a month ago

Ascletis Pha B Sustainability Profile

Company website

Ascletis Pharma Inc., commonly referred to as Ascletis, is a prominent biopharmaceutical company headquartered in China (CN). Founded in 2013, Ascletis has rapidly established itself in the biotechnology sector, focusing on the research, development, and commercialisation of innovative therapies for viral infections, liver diseases, and cancer. With a strong operational presence in major regions across Asia, Ascletis has achieved significant milestones, including the successful launch of its core products, which are distinguished by their advanced formulations and efficacy. The company is recognised for its commitment to addressing unmet medical needs, positioning itself as a leader in the competitive biopharmaceutical landscape. Ascletis continues to drive innovation, contributing to the global fight against serious health challenges.

DitchCarbon Score

How does Ascletis Pha B's carbon action stack up? DitchCarbon scores companies based on their carbon action and commitment to reducing emissions. Read about our methodology to learn more.

20

Industry Average

Mean score of companies in the Pharmaceutical Preparation Manufacturing industry. Comparing a company's score to the industry average can give you a sense of how well the company is doing compared to its peers.

31

Industry Benchmark

Ascletis Pha B's score of 20 is lower than 75% of the industry. This can give you a sense of how well the company is doing compared to its peers.

25%

Let us know if this data was useful to you

Ascletis Pha B's reported carbon emissions

In 2021, Ascletis Pharma Inc., headquartered in China (CN), reported total carbon emissions of approximately 2,180,270 kg CO2e. This figure includes 14,630 kg CO2e from Scope 1 emissions and 2,165,640 kg CO2e from Scope 2 emissions. The company has not disclosed any Scope 3 emissions data for this year. Comparatively, in 2018, Ascletis reported total emissions of about 2,064,900 kg CO2e, with 31,400 kg CO2e from Scope 1, 2,018,300 kg CO2e from Scope 2, and 15,200 kg CO2e from Scope 3. This indicates a slight increase in total emissions from 2018 to 2021. Despite these emissions figures, Ascletis has not set any specific reduction targets or climate pledges, nor have they cascaded any targets from parent or related organizations. The absence of defined climate commitments suggests a need for further action in aligning with industry standards for carbon reduction.

Unlock detailed emissions data

Access structured emissions data, company-specific emission factors, and source documents

20182021
Scope 1
31,400
00,000
Scope 2
2,018,300
0,000,000
Scope 3
15,200
-

How Carbon Intensive is Ascletis Pha B's Industry?

Very low
Low
Medium
High
Very high
Some industries are more carbon intensive than others. Ascletis Pha B's primary industry is Pharmaceutical Preparation Manufacturing, which is very low in terms of carbon intensity compared to other industries.

How Carbon Intensive is Ascletis Pha B's Location?

Very low
Low
Medium
High
Very high
The carbon intensity of the energy grid powering a company's primary operations has a strong influence on its overall carbon footprint. This request for Ascletis Pha B is in CN, which we do not have grid emissions data for.

Ascletis Pha B's Climate Goals (2030 & 2050)

Climate goals typically focus on 2030 interim targets and 2050 net-zero commitments, aligned with global frameworks like the Paris Agreement and Science Based Targets initiative (SBTi) to ensure alignment with global climate goals.

Ascletis Pha B has not publicly committed to specific 2030 or 2050 climate goals through the major frameworks we track. Companies often set interim 2030 targets and long-term 2050 net-zero goals to demonstrate measurable progress toward decarbonization.

Science Based Targets Initiative
Carbon Disclosure Project
The Climate Pledge
UN Global Compact
RE 100
Climate Action 100
Race To Net Zero
Reduction Actions

Compare Ascletis Pha B's Emissions with Industry Peers

Gilead Sciences

US
•
Pharmaceutical Preparation Manufacturing
Updated 4 days ago

Regeneron

US
•
Pharmaceutical Preparation Manufacturing
Updated 15 days ago

Abbvie

US
•
Pharmaceutical Preparation Manufacturing
Updated about 5 hours ago

Bristol-Myers Squibb

US
•
Pharmaceutical Preparation Manufacturing
Updated about 7 hours ago

Novartis

CH
•
Pharmaceutical Preparation Manufacturing
Updated 2 days ago

Merck And Co

US
•
Pharmaceutical Preparation Manufacturing
Updated about 5 hours ago

Let us know if this data was useful to you

Where does DitchCarbon data come from?

Discover our data-driven methodology for measuring corporate climate action and benchmarking against industry peers

Ditchcarbon
v251031.3
[email protected]+44 203 475 7875Ditch Carbon Ltd167-169 Great Portland StreetLondon W1W 5PF
UL Solutions verification badge
CDP logo
Gartner Cool Vendor 2025 badge
ProductPortalScope 3 Tool FunctionalityDataIntegrationsPricing
CustomersHaleonGrant ThorntonHikmaRead all stories
SolutionsProcurement teamsSustainability teamsPlatform ownersCarbon accountants
ResourcesCalculation MethodologyDocumentationBlogFAQOrganizationsIndustriesSBTI APITrust CentreChangelog
AboutTeamCareersLicense AgreementPrivacy